title: Gastrointestinal permeability during exercise: effects of aspirin and energy-containing beverages.
abstract: The purpose of this study was to determine whether aspirin (A) ingestion combined with prolonged exercise increases gastrointestinal permeability and whether consumption of a carbohydrate-containing (CHO) or a CHO + glutamine-containing (CHO+G) beverage would reduce this effect. Seventeen subjects completed six experiments. They ingested A (1,300 mg) or placebo (P) pills the evening before and before running 60 min at 70% maximal oxygen uptake. Also, before running they ingested a solution containing 5 g lactulose (L), 5 g sucrose (S), and 2 g rhamnose (R). During each trial, either a 6% CHO beverage, a 6% CHO+G (0.6%; 41 mM) beverage, or a water placebo (WP) was consumed. For 4 h after a run, all urine was collected to measure urinary excretion of L, R, and S. S excretion (percentage of dose ingested; measure of gastroduodenal permeability) was significantly greater (P < 0.05) during the A trial while the subjects drank the WP compared with all other trials. Administration of A also significantly increased L/R (measure of intestinal permeability) for the CHO and WP trials compared with all P trials. Ingestion the CHO or CHO+G beverages significantly reduced S excretion and L excretion when A was administered, but it did not reduce L/R. These results indicate that gastroduodenal and intestinal permeability increase after A ingestion during prolonged running and that ingestion of a CHO beverage attenuates the gastroduodenal effect but not the intestinal effect. Furthermore, addition of G to the CHO beverage provided no additional benefit in reducing gastroduodenal or intestinal permeability.
authors.affiliation: Department of Exercise Science, University of Iowa, Iowa City, Iowa 52242, USA.
authors.forename: G P
authors.initials: GP
authors.lastname: Lambert
authors.forename: L J
authors.initials: LJ
authors.lastname: Broussard
authors.forename: B L
authors.initials: BL
authors.lastname: Mason
authors.forename: W J
authors.initials: WJ
authors.lastname: Mauermann
authors.forename: C V
authors.initials: CV
authors.lastname: Gisolfi
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology*; D001835:Body Weight / Q000502:physiology; D004040:Dietary Carbohydrates / Q000494:pharmacology*; D002149:Energy Intake / Q000502:physiology*; D015444:Exercise / Q000502:physiology*; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D007792:Lactulose / Q000378:metabolism; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects; D012210:Rhamnose / Q000378:metabolism; D013395:Sucrose / Q000652:urine; D013546:Sweating / Q000502:physiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004040:Dietary Carbohydrates; D007792:Lactulose; D013395:Sucrose; D012210:Rhamnose; D001241:Aspirin